



NORGINE ANNOUNCES THE LAUNCH OF SETOFILM[®] ONDANSETRON ORAL DISPERSIBLE FILM

31 May 2013. Norgine today announced the launch of SETOFILM[®], an orally dispersible film (ODF) formulation of ondansetron.

SETOFILM[®] was exclusively licensed to Norgine in Europe, Australia, New Zealand, South Africa, North Africa and the Middle East from Applied Pharma Research s.a. in December 2011.

SETOFILM[®] is the first prescription product developed as an ODF formulation to be registered in Europe.

SETOFILM[®] is indicated for the prevention and treatment of Chemotherapy Induced Nausea and Vomiting ("CINV") in adults as well as children aged 6 months or above, Radiotherapy Induced Nausea and Vomiting ("RINV") in adults and the prevention and treatment of Post-Operative Nausea and Vomiting (PONV) in adults and children aged 4 years or above¹.

The product is available in 4mg and 8mg doses. Once placed in the mouth, it dissolves in a few seconds and is swallowed with saliva without the need for water².

Norgine's Chief Operating Officer Peter Martin commented: "I am pleased Norgine is making this new oral presentation of SETOFILM[®] available for patients across the EU. SETOFILM[®] may help and benefit people suffering from serious conditions".

ENDS

About Norgine

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2012, Norgine's net product sales were c€250 million and the company employs over a 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas: MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel preparation for use prior to any procedure that requires a clean colon, KLEAN-PREP[®] for large
INT/SET/0513/0028

**Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600**

bowel preparation prior to colonoscopy or surgery, XIFAXAN® (XIFAXANTA™) for the treatment of travellers' diarrhoea and the reduction in recurrence of episodes of overt hepatic encephalopathy, ORAMORPH® for the treatment of moderate to severe pain associated with cancer and our supportive care portfolio: SETOFILM®, SAVENE®, DANTRIUM®, XEROTIN® and PROTHER®.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengood, UK and Dreux, France. For more information: www.norgine.com.

About APR Applied Pharma Research s.a.

APR is an independent, international and integrated Healthcare Company headquartered in Switzerland and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR's development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis. For press releases and other company information visit: www.apr.ch

SETOFILM® is a registered trademark of APR Applied Pharma Research s.a., exclusively licensed to the Norgine group of companies in the European Union. Product under licence of APR Applied Pharma Research s.a.

SETOFIM® is a registered trademark of APR Applied Pharma Research s.a., exclusively licensed to the Norgine group of companies in Norway. Product under licence of APR Applied Pharma Research s.a.

Product under licence from Alfa Wassermann S.p.A. XIFAXAN® is a registered trademark of the Alfa Wassermann group of companies, licensed to the Norgine group of companies.

Media Contacts

Isabelle Jouin: Tel: +44 (0) 1895 453 643; Mobile: + 44 (0) 771 406 1327

Julie Hornby Winfield: Tel: +44 (0) 1895826642; Mobile: +44 (0) 7833 238440

References

1. SETOFILM® Summary of Product Characteristics. Norgine, 2013.
2. Reiner V, Giarratana N, Monti NC, *et al.* Rapidfilm®: An innovative pharmaceutical form designed to improve patient compliance. Int J Pharmaceutics 2010;393;55-60.

INT/SET/0513/0028

**Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600**